Dilip Bhandare Saurabh
Nashik Gramin Shikshan Prasarak Mandal's, College of Pharmacy, Bramha Valley Educational Campus, Anjaneri, Trambak, Nashik 422213, Maharashtra, India.
J Pharm Pharmacol. 2025 Jan 6;77(1):18-31. doi: 10.1093/jpp/rgae074.
The study aims to explore the potential of medicinal plants and their phytoconstituents as effective inhibitors of the coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. The focus is on investigating specific medicinal plants known for their pharmacological properties, such as: antioxidant, anti-inflammatory, and immunomodulatory effects, to determine their viability in developing COVID-19 treatments.
This study involves a comprehensive study of medicinal plants, including: Withania somnifera (Ashwagandha) and Ocimum sanctum (Holy Basil), known for their beneficial health effects. Molecular docking studies were conducted to assess the interactions between phytoconstituents from these plants and SARS-CoV-2 proteins. The compounds' drug-like characteristics and safety profiles were also evaluated to determine their potential as therapeutic agents.
The molecular docking studies revealed that the phytoconstituents from the studied medicinal plants exhibit favourable interactions with SARS-CoV-2 proteins, suggesting their potential as therapeutic targets. These compounds demonstrated promising drug-like characteristics and safety profiles, indicating their suitability for further development as COVID-19-fighting medications.
The results indicate that medicinal plants and their bioactive substances hold significant potential for developing therapies against COVID-19. The ability of these organic substances to interact with key viral proteins and provide various therapeutic benefits highlights their potential as multi-functional treatment options. However, further research is necessary to confirm these findings and to understand the full scope of their therapeutic efficacy and safety in clinical settings.
Medicinal plants and their phyto-constituents represent a promising avenue for developing effective treatments for COVID-19. The favourable interactions with SARS-CoV-2 proteins and the promising drug-like characteristics observed in this study suggest that these natural compounds could be integral in the fight against the COVID-19 pandemic. Further research and clinical trials are essential to fully validating their potential and translating these findings into practical medical applications.
本研究旨在探索药用植物及其植物成分作为2019冠状病毒病（COVID - 19，由严重急性呼吸综合征冠状病毒2型[SARS-CoV-2]病毒引起）有效抑制剂的潜力。重点是研究以其药理特性（如抗氧化、抗炎和免疫调节作用）而闻名的特定药用植物，以确定它们在开发COVID - 19治疗方法中的可行性。
本研究对药用植物进行了全面研究，包括：因对健康有益而闻名的印度人参（Withania somnifera）和罗勒（Ocimum sanctum）。进行了分子对接研究，以评估这些植物的植物成分与SARS-CoV-2蛋白之间的相互作用。还评估了这些化合物的类药物特性和安全性，以确定它们作为治疗剂的潜力。
分子对接研究表明，所研究药用植物的植物成分与SARS-CoV-2蛋白表现出良好的相互作用，表明它们有作为治疗靶点的潜力。这些化合物显示出有前景的类药物特性和安全性，表明它们适合进一步开发为抗击COVID - 19的药物。
结果表明，药用植物及其生物活性物质在开发针对COVID - 19的疗法方面具有巨大潜力。这些有机物质与关键病毒蛋白相互作用并提供多种治疗益处的能力突出了它们作为多功能治疗选择的潜力。然而，需要进一步研究来证实这些发现，并了解它们在临床环境中的治疗效果和安全性的全貌。
药用植物及其植物成分是开发COVID - 19有效治疗方法的一个有前景的途径。本研究中观察到的与SARS-CoV-2蛋白的良好相互作用以及有前景的类药物特性表明，这些天然化合物可能在抗击COVID - 19大流行中发挥重要作用。进一步的研究和临床试验对于充分验证它们的潜力并将这些发现转化为实际医学应用至关重要。
